Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pathology · HER2-Positive Breast Carcinoma

Reading Your Pathology Report

At a Glance

Your HER2-positive breast cancer pathology report does more than confirm HER2 status: it combines protein staining and, when needed, gene testing with ER/PR results, tumor size, grade, lymph nodes, cancer in small vessels, and surgical margins to guide treatment.

Deciphering a pathology report can feel like learning a foreign language. However, these results are the foundation of your entire treatment plan. The report doesn’t just say “cancer”; it describes the specific biological “fingerprint” of your tumor, which tells your care team exactly which tools will be most effective.

The HER2 Testing Process

Testing for HER2 is typically done in a two-step process. The first step is Immunohistochemistry (IHC), which uses special dyes to stain the HER2 proteins on the surface of cancer cells [1].

The IHC test provides a score from 0 to 3+:

  • 0 or 1+ (Negative): There is little to no HER2 protein on the cell surface. These tumors are HER2-negative. Current guidelines emphasize that distinguishing between 0 and 1+ is important, as some newer targeted treatments for advanced disease may be options for those with a 1+ score (often called HER2-low), though this does not change early-stage treatment protocols [2] [3].
  • 2+ (Equivocal): The staining is weak or moderate. This result is not a “yes” or a “no,” so a second test called In Situ Hybridization (ISH)—often specifically FISH—is required to look directly at the genes inside the cells [4].
  • 3+ (Positive): There is intense, complete staining in more than 10% of the cells. This confirms the cancer is HER2-positive [5].

Decoding the ISH “Tie-Breaker”

If your IHC was 2+, the laboratory performs ISH to see if the ERBB2 gene is amplified (meaning there are too many copies). Doctors look at two main numbers: the average number of HER2 gene copies and the HER2/CEP17 ratio (comparing HER2 genes to a control gene on the same chromosome) [6].

Based on these numbers, your tumor is placed into one of five groups:

  • Group 1 (Positive): Ratio is ≥\ge 2.0 and there are ≥\ge 4.0 HER2 copies per cell. This is a clear positive [7].
  • Groups 2, 3, and 4: These are complex cases where the genes and proteins don’t perfectly match. A pathologist must perform an integrated review of the IHC slides and the ISH results to make a final positive or negative determination. Rely on your pathologist’s final integrated interpretation rather than the raw group number [4] [8].
  • Group 5 (Negative): Ratio is < 2.0 and there are < 4.0 HER2 copies. This is a clear negative [6].

The Role of Hormone Receptors (HR)

Your report will also list your Hormone Receptor status, specifically Estrogen Receptor (ER) and Progesterone Receptor (PR).

  • HR-Positive / HER2-Positive: If you are ER+, PR+, and HER2+, your cancer is fueled by both hormones and the HER2 protein [9].
  • HR-Negative / HER2-Positive: If you are negative for hormone receptors but positive for HER2, the cancer relies primarily on the HER2 pathway for growth [10]. (Note: Your doctor might mention intrinsic molecular subtypes like “HER2-enriched” which requires advanced genomic testing, but HR-negative/HER2-positive is the standard clinical term).

There is constant “crosstalk” between these pathways. Because the HER2 and estrogen pathways can influence each other, your doctor will likely recommend both HER2-targeted therapy and hormone-blocking therapy if you are HR-positive [10] [11].

Pathology Report Completeness Checklist

To ensure your team has all the information needed, verify that your reports include these key elements (note that some details like margins only apply to a surgical excision, not an initial core biopsy) [12] [13]:

  1. Tumor Size: Measured in centimeters (e.g., pT1, pT2).
  2. Histologic Grade: Usually the Nottingham Grade (1, 2, or 3), which describes how abnormal the cells look under a microscope [14].
  3. Nodal Status: Whether the cancer has spread to nearby lymph nodes (e.g., pN0, pN1).
  4. Lymphovascular Invasion (LVI): Whether cancer cells have been found inside the small blood or lymph vessels within the breast [15].
  5. Margin Status (Surgical Report): Whether there is a clear boundary (no ink on the tumor) around the removed tissue [16].
  6. Receptor Status: Clear results for ER, PR, and HER2 (including the IHC score and ISH results if applicable) [17].

Common questions in this guide

What do the HER2 IHC scores 0, 1+, 2+, and 3+ mean?
An IHC score of 0 or 1+ means little or no HER2 protein is detected and is generally classified as HER2-negative, although 1+ can be relevant to some treatments for advanced disease. A 2+ result is equivocal and needs ISH testing. A 3+ result, with strong complete staining in more than 10% of tumor cells, confirms HER2-positive breast cancer.
What happens after a HER2 IHC result of 2+?
A 2+ result is equivocal, so the laboratory usually performs ISH, often called FISH, to look for extra copies of the ERBB2 gene and calculate the HER2/CEP17 ratio. For complex results, the pathologist reviews the gene test and IHC findings together and issues a final interpretation, which is more important than the group number alone.
How do ER and PR results affect treatment for HER2-positive breast cancer?
If the cancer is positive for ER or PR, hormones may also help it grow, so treatment may include both HER2-targeted therapy and hormone-blocking therapy. When both hormone receptors are negative, treatment is guided primarily by the HER2 result and other clinical factors.
Which findings are important in a breast cancer pathology report?
Important details include tumor size, Nottingham grade, lymph-node status, lymphovascular invasion, ER and PR results, and the HER2 IHC or ISH findings. After surgery, the report may also state whether the margins are clear, giving the care team information for treatment planning.
What do Nottingham grade and lymphovascular invasion mean?
Nottingham grade describes how abnormal the cancer cells look under a microscope, using grades 1 through 3. Lymphovascular invasion means cancer cells were seen in small blood or lymph vessels in the breast; your team considers this finding with the rest of the report when discussing recurrence risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my exact IHC score (0, 1+, 2+, or 3+), and what was the percentage of cells that stained?
  2. 2.If my score was 2+, which ISH group (1–5) did my tumor fall into, and what was the final integrated HER2 interpretation?
  3. 3.How does my hormone receptor (ER and PR) status change the specific sequence of drugs you are recommending?
  4. 4.What was the 'Nottingham grade' of my tumor, and what does that tell us about its microscopic features?
  5. 5.Was lymphovascular invasion (LVI) present, and how does that affect my risk of the cancer returning?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

    Wolff AC, Hammond MEH, Allison KH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(20)):2105-2122 doi:10.1200/JCO.2018.77.8738.

    PMID: 29846122
  2. 2

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.

    Wolff AC, Somerfield MR, Dowsett M, et al.

    Archives of pathology & laboratory medicine 2023; (147(9)):993-1000 doi:10.5858/arpa.2023-0950-SA.

    PMID: 37303228
  3. 3

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

    Wolff AC, Somerfield MR, Dowsett M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

    PMID: 37284804
  4. 4

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

    Wolff AC, Hammond MEH, Allison KH, et al.

    Archives of pathology & laboratory medicine 2018; (142(11)):1364-1382 doi:10.5858/arpa.2018-0902-SA.

    PMID: 29846104
  5. 5

    Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.

    Varga Z, Noske A

    PloS one 2015; (10(10)):e0140652 doi:10.1371/journal.pone.0140652.

    PMID: 26473483
  6. 6

    HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

    Press MF, Sauter G, Buyse M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(29)):3518-3528 doi:10.1200/JCO.2016.66.6693.

    PMID: 27573653
  7. 7

    Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice.

    Press MF, Villalobos I, Santiago A, et al.

    Archives of pathology & laboratory medicine 2016; (140(11)):1250-1258 doi:10.5858/arpa.2016-0009-OA.

    PMID: 27081877
  8. 8

    Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0).

    Wilcock D, Sirohi D, Albertson D, et al.

    Archives of pathology & laboratory medicine 2024; (148(8)):890-897 doi:10.5858/arpa.2023-0275-OA.

    PMID: 37934954
  9. 9

    Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.

    Larionov AA

    Frontiers in oncology 2018; (8()):89 doi:10.3389/fonc.2018.00089.

    PMID: 29670855
  10. 10

    Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.

    Thanopoulou E, Khader L, Caira M, et al.

    Cancers 2020; (12(11)) doi:10.3390/cancers12113317.

    PMID: 33182657
  11. 11

    Breast cancer.

    Harbeck N, Penault-Llorca F, Cortes J, et al.

    Nature reviews. Disease primers 2019; (5(1)):66 doi:10.1038/s41572-019-0111-2.

    PMID: 31548545
  12. 12

    Significance of prognostic indicators in infiltrating duct carcinoma breast: Scenario in developing country.

    Krishnamurthy J, Kumar PS

    Indian journal of cancer 2016; (53(1)):34-8 doi:10.4103/0019-509X.180834.

    PMID: 27146735
  13. 13

    New and Important Changes in the TNM Staging System for Breast Cancer.

    Hortobagyi GN, Edge SB, Giuliano A

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018; (38()):457-467 doi:10.1200/EDBK_201313.

    PMID: 30231399
  14. 14

    Prognostic and predictive parameters in breast pathology: a pathologist's primer.

    Allison KH

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(Suppl 1)):94-106 doi:10.1038/s41379-020-00704-7.

    PMID: 33154551
  15. 15

    Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.

    Henry NL, Somerfield MR, Abramson VG, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2303-11 doi:10.1200/JCO.2015.65.8609.

    PMID: 27001586
  16. 16

    MRI-Based Assessment of Margin Status Determinants, Preoperative Predictors, and Prognostic Outcomes in Breast-Conserving Surgery Following Neoadjuvant Therapy.

    Liu X, Liu Y, Ma T, et al.

    World journal of surgery 2025; (49(10)):2620-2629 doi:10.1002/wjs.70072.

    PMID: 40855824
  17. 17

    Prognostic and predictive biomarkers in breast cancer: Past, present and future.

    Nicolini A, Ferrari P, Duffy MJ

    Seminars in cancer biology 2018; (52(Pt 1)):56-73 doi:10.1016/j.semcancer.2017.08.010.

    PMID: 28882552

This page explains HER2-positive breast cancer pathology results for informational purposes only and does not constitute medical advice. Your pathologist and oncology team should interpret your report and recommend care for your specific situation.

Get notified when new evidence is published on HER2 positive breast carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.